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Editorial on the Research Topic
Women’s Lung
The high incidence of chronic lung diseases generates a substantial health problem worldwide (ERS
White Book, https://www.erswhitebook.org/). Recently, increasing recognition of the importance
of the disease’s phenotypes was noted. Most lung diseases are regarded as a whole. In the
epidemiological reports, the attention is focused on age and race rather than sex, although there is
evidence that sex influences the expression of respiratory disease as well. The epidemiology of lung
diseases, the susceptibility to risk factors, and the clinical course of the disease all differ in males and
females. The aim of separate consideration of lung diseases in the female population is possibly a
subsequent modification of diagnostic procedures and establishing additional specific criteria in the
treatment approach, which might result in specific prophylactic programs and targeted therapies.
It would be in line with modern personalized and precision medicine. Recent recognition of the
specific and different course of lung cancer and chronic obstructive lung disease (COPD) in the
female population represents a good example (1, 2).
With evidence that female phenotypes are often under-recognized and under-treated,
addressing the “female lung” is an important challenge. On the basis of this first-of-its-kind
Research Topic, we would like to better the collective understanding of the value of the recognition
of the role the female sex has in chronic lung diseases and to translate this knowledge into clinical
practice. This will require time and complex research studies. Some respiratory scientific societies
already have a section dedicated to diseases in females, France being a prime example (https://splf.
fr/femmes-et-poumon).
The use of proper medical terminology in the exchange of knowledge is crucial. This applies,
for example, to the terms of sex and gender, which are not the same. “Sex” refers to biology and
“gender” to behavioral and social determinants (3, 4). On the one hand, sex is an influencing factor
on gender; on the other hand, gender influences the modification of epigenetic changes and thus
the risk of some diseases. The use of terminology requires caution, and this should be kept in mind
during study planning.
Most of the articles submitted to Research Topic Women’s Lung are reviews, showing that the
authors are familiar with this problem, but original research studies are, in many aspects, urgently
needed. Most articles in this Issue describe risk factors for female lung diseases, such as smoking,
genetics, hormonal status, and the microbiome.
Interestingly, the subject of one article is currently very important, and it relates to
smoking habits and COVID-19. Milhatan et al. have conducted a systemic review on the
impact of tobacco smoking on SARS-CoV-2 infection and COVID-19 disease. Smoking has
been shown to be a risk factor for COVID-19 by increasing susceptibility to infection
and modulating the expression of angiotensin-converting enzyme 2 (ACE-2). The authors
present their results compared with the existing literature, meta-analyses on the relationship
between smoking and COVID-19 incidence, hospitalization, disease severity, mortality, and
prevention in the context of biological sex. With one exception, cigarette smoking has been
found to increase the severity of the COVID-19 disease and worsen prognosis in males.
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The higher proportion of smokers among males is one of the
possible explanations, and others could involve better hygiene
and the protective role of estrogens in females. Authors have
concluded that in the time of the SARS-CoV-2 pandemic, an
additional indication for antinicotine programs exists, especially
among women. This shows a new direction for future studies.
Estrogens and lung cancer is a subject of review by
experienced authors in the field, such as Rodriguez-Lara
and Avila-Costa Sexual dimorphism causes different clinical
characteristics of lung cancer in females vs. males, different
distributions of histological types, and different genetic profile.
The authors present different risk factors for female lung cancer
apart from well-known active smoking, which is still popular
among young women, including the following: second-hand
(passive) smoking, wood smoke exposure, inhalation of cooking-
derived products, and ambient air pollutants. The role of
estrogens, estrogens receptors, and the enzymatic pathway of
estrogen production by aromatase in the lung and carcinogenesis
was described in detail and illustrated comprehensively. In spite
of the role of estrogens in carcinogenesis, there is no direct
impact on relation of hormonal status and lung cancer course
and treatment outcomes. However, aromatase inhibitors and
inhibitors of estrogens receptors were effective in experimental
studies and clinical trials.
The influence of sex on chronic lung diseases by modification
of the gut–lungmicrobiome was a topic of a comprehensive study
by Beauruelle et al. The authors use the term “microgenderome,”
showing, on the basis of many observations and animal models,
that the airways (in connection with the gut) are characterized
by the steady-state microbiome. The gut–lung axis is capable
of modifying the immune system. Thanks to new genetic
techniques, the knowledge on lung microflora has developed,
showing that the lung is not sterile. It was shown by the
authors that the distribution of lung diseases differs between the
male and female populations, with the prevalence of chronic
entities being shown among females. There is a different
distribution of pathogens in cystic fibrosis: the most serious
are observed in the female sex, but the acute community-
acquired infections are most often noted among males. The
role of estrogens in the modification of anti-inflammatory host
defense is well-established: these hormones enhance the immune
response, change mucus properties and thus providing a more
protective function, and modify the bacterial–host interaction.
To summarize, this article represents a basis for further studies
that are very important for possible modification of treatment
and prevention of chronic respiratory diseases.
Endometriosis belongs strictly to female diseases of the
respiratory tract. Wang et al. described in their article a
case report confirmed by data from literature concerning
endometriosis-related pleural effusion. They highlighted that this
clinical problem should be taken into account by physicians
in the case of spontaneous pneumothorax. Interestingly the
authors present confirmation of endometriosis-related pleural
effusion by cytological examination. The endometrial origin of
the clusters of glandular cells could be confirmed by a positive
reaction to estrogen and progesterone receptors. The results of
the literature search showed that endometriosis-related PE is
observed in young women aged 35+/−8 years old, the main
symptoms being catamenial chest pain, dyspnea, and cough
(50.7,74.6, and 26.9% respectively). The chest CT findings include
pleural effusion (79.1% unilateral), pleural thickening (8.6%), and
often pneumothorax.
Sexual dimorphism of the respiratory tract begins in utero.
Tremblay and Morin-Labbé present their experimental model,
which illustrates the local production and action of androgens
in lung development. This is a model of intracrinology,
e.g., “production of active sex steroids in situ within the
cells where the action takes place”. In these experimental
models, androgen receptors were found with similar distribution
in males and females, and the local activity of steroids
and sex hormones in lung development as well as causes
of bronchopulmonary dysplasia are presented. These results
correspond well to the opinion that inappropriate lung
development might be responsible for obstructive lung diseases
in adults1.
To conclude, the idea of a Research Topic dedicated to lung
diseases in females turned out to be interesting for authors and
revealed a wide range of issues worth considering for further
research and popularization.
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